Transgene Biotek Limited (BOM:526139)

Transgene Biotek Income Statement

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Revenue	-5.06	2.61	2.35	0.55	0.87	1.7
Revenue Growth (YoY)	-	10.98%	326.32%	-36.44%	-48.87%	4642.12%
Cost of Revenue	-	-	0.03	0.66	-0.45	0.64
Gross Profit	-5.06	2.61	2.32	-0.11	1.32	1.05
Selling, General & Admin	1.84	3.15	3.18	3.04	2.93	2.5
Other Operating Expenses	8.54	10.68	5.2	7.38	3	3.77
Operating Expenses	12.11	14.77	9.3	59.91	105.17	105.36
Operating Income	-17.17	-12.16	-6.98	-60.03	-103.85	-104.31
Interest Expense	-9.75	-2.44	-1.4	-1.81	-2.29	-2.71
Other Non Operating Income (Expenses)	1.75	1.75	1.75	1.75	1.75	1.75
EBT Excluding Unusual Items	-25.17	-12.84	-6.63	-60.09	-104.39	-105.26
Other Unusual Items	6.08	6.08	0.07	-	0.37	0.92
Pretax Income	-19.09	-6.76	-6.56	-60.09	-104.02	-104.35
Net Income	-19.09	-6.76	-6.56	-60.09	-104.02	-104.35
Net Income to Common	-19.09	-6.76	-6.56	-60.09	-104.02	-104.35
Shares Outstanding (Basic)	75	76	76	76	76	76
Shares Outstanding (Diluted)	75	76	76	76	76	76
EPS (Basic)	-0.25	-0.09	-0.09	-0.79	-1.37	-1.38
EPS (Diluted)	-0.26	-0.09	-0.09	-0.79	-1.37	-1.38
Free Cash Flow	-	-5.04	0.05	-0.01	0.98	-0.15
Free Cash Flow Per Share	-	-0.07	0.00	-	0.01	-0.00
Gross Margin	-	100.00%	98.72%	-20.33%	152.09%	62.05%
Operating Margin	-	-466.40%	-297.32%	-10894.01%	-11979.30%	-6151.93%
Profit Margin	-	-259.34%	-279.06%	-10904.90%	-11998.40%	-6154.34%
Free Cash Flow Margin	-	-193.21%	1.96%	-2.36%	112.81%	-8.74%
EBITDA	-16.23	-11.23	-6.06	-10.53	-4.61	-5.23
EBITDA Margin	-	-	-258.02%	-	-	-
D&A For EBITDA	0.94	0.93	0.92	49.5	99.24	99.08
EBIT	-17.17	-12.16	-6.98	-60.03	-103.85	-104.31
EBIT Margin	-	-	-297.32%	-	-	-
Revenue as Reported	2.77	10.44	4.18	2.31	2.99	4.36
Advertising Expenses	-	0.01	0.02	0.02	0.04	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.